JP2008527002A - 神経変性障害および血液凝固障害を予防および処置するための新規組成物 - Google Patents

神経変性障害および血液凝固障害を予防および処置するための新規組成物 Download PDF

Info

Publication number
JP2008527002A
JP2008527002A JP2007551449A JP2007551449A JP2008527002A JP 2008527002 A JP2008527002 A JP 2008527002A JP 2007551449 A JP2007551449 A JP 2007551449A JP 2007551449 A JP2007551449 A JP 2007551449A JP 2008527002 A JP2008527002 A JP 2008527002A
Authority
JP
Japan
Prior art keywords
compound
formula
sirtuin activating
attendant definitions
further embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007551449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008527002A5 (https=
Inventor
マイケル ミルバーン，
ジル ミルン，
クリストファー エイチ． ウェストファール，
カール ディー． ノーミングトン，
ジェニファー フジイ，
ミシェル ディップ，
ピーター エリオット，
Original Assignee
サートリス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サートリス ファーマシューティカルズ， インコーポレイテッド filed Critical サートリス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2008527002A publication Critical patent/JP2008527002A/ja
Publication of JP2008527002A5 publication Critical patent/JP2008527002A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007551449A 2005-01-13 2006-01-13 神経変性障害および血液凝固障害を予防および処置するための新規組成物 Withdrawn JP2008527002A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US64392105P 2005-01-13 2005-01-13
US66717905P 2005-03-30 2005-03-30
US69278505P 2005-06-22 2005-06-22
US73652805P 2005-11-14 2005-11-14
US75360605P 2005-12-23 2005-12-23
PCT/US2006/001428 WO2006076681A2 (en) 2005-01-13 2006-01-13 Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012274969A Division JP2013082723A (ja) 2005-01-13 2012-12-17 神経変性障害および血液凝固障害を予防および処置するための新規組成物

Publications (2)

Publication Number Publication Date
JP2008527002A true JP2008527002A (ja) 2008-07-24
JP2008527002A5 JP2008527002A5 (https=) 2009-02-19

Family

ID=36678263

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007551449A Withdrawn JP2008527002A (ja) 2005-01-13 2006-01-13 神経変性障害および血液凝固障害を予防および処置するための新規組成物
JP2012274969A Withdrawn JP2013082723A (ja) 2005-01-13 2012-12-17 神経変性障害および血液凝固障害を予防および処置するための新規組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012274969A Withdrawn JP2013082723A (ja) 2005-01-13 2012-12-17 神経変性障害および血液凝固障害を予防および処置するための新規組成物

Country Status (6)

Country Link
US (1) US20060276393A1 (https=)
EP (1) EP1850840A2 (https=)
JP (2) JP2008527002A (https=)
AU (1) AU2006204699B2 (https=)
CA (1) CA2595159A1 (https=)
WO (1) WO2006076681A2 (https=)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542296A (ja) * 2005-05-25 2008-11-27 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン活性化剤による眼障害の処置
JP2012500283A (ja) * 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク． （ｒ）−プラミペキソールを使用した組成物並びにその方法
JP2013241380A (ja) * 2012-05-22 2013-12-05 Apion Japan Kk サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤
JP2014510064A (ja) * 2011-02-25 2014-04-24 ザ ジョンズ ホプキンス ユニバーシティ Ｎｒｆ２活性剤としてのカルコン誘導体
JP2014516359A (ja) * 2011-04-15 2014-07-10 ネステク ソシエテ アノニム サーチュイン遺伝子発現の調節方法
KR101466700B1 (ko) * 2011-02-28 2014-11-28 동아대학교 산학협력단 Ｓｉｒ－ＦＯＸＯ 신호전달체계 활성인자를 포함하는 퇴행성 신경질환 치료용 조성물
JP2016507538A (ja) * 2013-02-07 2016-03-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 置換キノキサリン誘導体およびｍＧｌｕＲ４の正のアロステリックモジュレーターとしてのそれらの使用
JP2016041680A (ja) * 2014-04-25 2016-03-31 森永製菓株式会社 サーチュイン発現増強剤
JP2016094406A (ja) * 2014-11-06 2016-05-26 森永製菓株式会社 アストロサイト分化誘導剤及びｇｆａｐ発現誘導剤
JP2016518448A (ja) * 2013-05-13 2016-06-23 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節剤としての置換架橋尿素類似体
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
JP2017206526A (ja) * 2011-06-29 2017-11-24 ザ ジェネラル ホスピタル コーポレイション 雌性生殖細胞における生体エネルギー状態を増強するための組成物及び方法
JP2018517728A (ja) * 2015-06-15 2018-07-05 ラッシュ・ユニバーシティ・メディカル・センター 脳由来のＰＰＡＲαリガンド
US10028940B2 (en) 2013-08-13 2018-07-24 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
KR101922903B1 (ko) 2016-03-11 2018-11-28 전북대학교산학협력단 항신경변성 천연물 소재의 스크리닝 방법
US10195183B2 (en) 2013-08-13 2019-02-05 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US10383857B2 (en) 2013-07-12 2019-08-20 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
WO2020145331A1 (ja) * 2019-01-09 2020-07-16 公立大学法人大阪 神経変性疾患の予防又は治療薬
WO2020153434A1 (ja) * 2019-01-25 2020-07-30 第一三共株式会社 ピラゾール化合物
JP2022523919A (ja) * 2019-02-05 2022-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 神経変性疾患を治療するための物質および方法
JP2022150176A (ja) * 2021-03-26 2022-10-07 国立大学法人九州大学 サーチュイン活性化剤、食品、および化粧品
JP2024511616A (ja) * 2021-03-25 2024-03-14 ラモット アット テル アビブ ユニバーシティ， リミテッド 活性依存性神経栄養因子（ａｃｔｉｖｉｔｙ ｄｅｐｅｎｄｅｎｔ ｎｅｕｒｏｔｒｏｐｈｉｃ ｆａｃｔｏｒ、ａｄｎｆ）ポリペプチドを含む組成物及び物品

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009601A1 (en) * 2002-07-15 2004-01-15 The Regents Of The University Of California Methods for the regeneration and transformation of cotton
CA2529510A1 (en) 2003-07-01 2005-01-13 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US20090169585A1 (en) * 2003-10-23 2009-07-02 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US7714161B2 (en) * 2004-01-20 2010-05-11 Brigham Young University Sirtuin activating compounds and methods for making the same
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
CN102793972A (zh) 2004-12-27 2012-11-28 范因斯坦医学研究院 通过电刺激迷走神经治疗炎症性疾病
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
AU2006218403A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060229265A1 (en) * 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
ES2524922T3 (es) 2005-05-10 2014-12-15 Intermune, Inc. Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007008548A2 (en) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US7960605B2 (en) * 2006-03-17 2011-06-14 BioMaker Pharmaceuticals, Inc. Methods for testing for caloric restriction (CR) mimetics
WO2008011083A2 (en) 2006-07-18 2008-01-24 Cornell Research Foundation, Inc. Compounds for enhancing arginase activity and methods of use thereof
WO2008011538A2 (en) 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory
WO2008027379A2 (en) * 2006-08-29 2008-03-06 Sirtris Pharmaceuticals, Inc. Indicators of sirtuin activity and methods of use thereof
US20100144885A1 (en) * 2006-09-29 2010-06-10 The Board Of Trustees Of The University Of Illinois Histone acetyl transferase activators and histone deacetylase inhibitors in the treatment of alcoholism
AU2007314141A1 (en) * 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
US20080249103A1 (en) * 2006-11-15 2008-10-09 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof
US8778986B1 (en) * 2007-01-25 2014-07-15 University Of South Florida Treatment of glycogen synthase kinase-based disease
US8802638B1 (en) * 2007-01-25 2014-08-12 University Of South Florida Flavonoid treatment of glycogen synthase kinase-based disease
CA2681110A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US9884031B2 (en) * 2007-05-09 2018-02-06 The Trustees Of The University Of Pennsylvania Use of HDAC inhibitors for treatment of cardiac rhythm disorders
WO2008138943A2 (en) * 2007-05-14 2008-11-20 Universite Libre De Bruxelles Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies
WO2009015179A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
WO2009018326A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Soluble pyrone analogs methods and compositions
JP5337405B2 (ja) 2007-09-17 2013-11-06 ザ・ホスピタル・フォー・シック・チルドレン ゴーシェ病の治療方法
WO2009054994A2 (en) * 2007-10-23 2009-04-30 President And Fellows Of Harvard College Sirt-3 related methods and compositions for mimicking exercise
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
EP2259782A4 (en) * 2008-03-03 2013-01-23 Nad Life Pty Ltd PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHOD FOR THEIR USE IN THE TREATMENT OF CELL DISEASES
WO2009118338A2 (en) * 2008-03-27 2009-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of a polyphenolic type compound for preventing or treating a polyglutamine expansion neurodegenerative disease
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
ITBS20080120A1 (it) * 2008-06-10 2009-12-11 Uni Degli Studi Brescia Composizione farmaceutica e suo uso
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
WO2010031043A2 (en) * 2008-09-15 2010-03-18 Georgetown University Reducing or preventing neuroinflammation or neurotoxicity
WO2010042841A1 (en) * 2008-10-09 2010-04-15 University Of North Texas Health Science Center Combination therapies for the treatment of degenerative inflammatory conditions of the nervous system
WO2010056880A1 (en) * 2008-11-12 2010-05-20 The Trustees Of The University Of Pennsylvania Utrophin promoter activity upregulation for the treatment of muscular dystrophy
ES2452484T3 (es) 2008-11-18 2014-04-01 Setpoint Medical Corporation Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US20120129923A1 (en) * 2009-05-20 2012-05-24 Nutracryst Therapeutics Private Limited Pharmaceutical co-crystals of quercetin
WO2010144578A2 (en) 2009-06-09 2010-12-16 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
PH12012500382A1 (en) 2009-09-03 2012-10-22 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
CN105126248B (zh) 2009-12-23 2018-06-12 赛博恩特医疗器械公司 用于治疗慢性炎症的神经刺激设备和系统
WO2011163241A2 (en) * 2010-06-21 2011-12-29 Georgetown University Neuroprotective compounds
US20120058088A1 (en) * 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
WO2012008549A1 (ja) 2010-07-15 2012-01-19 武田薬品工業株式会社 複素環化合物
US9499790B2 (en) 2010-08-26 2016-11-22 Kyoto University Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells
RU2013114390A (ru) 2010-08-31 2014-10-10 СНУ Ар энд ДиБи ФАУНДЕЙШН Применение фетального репрограммирования посредством ppar-дельта-агониста
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
CA2823753C (en) 2011-01-05 2019-03-12 Bioenergenix Llc Heterocyclic compounds for the inhibition of pask
BR112013022147A2 (pt) 2011-03-02 2017-04-25 Bioenergenix composto, composição farmacêutica, método de inibição da pask, método de tratamento de uma doença, método para alcançar um efeito em um paciente e método de tratamento de uma doença mediada pela pask
US8916561B2 (en) 2011-03-02 2014-12-23 Bioenergenix, Llc Substituted quinoxaline compounds for the inhibition of PASK
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP3345901A3 (en) * 2011-06-29 2018-09-12 President and Fellows of Harvard College Small molecules as antiaging agents
CN102887925B (zh) * 2011-07-21 2015-08-12 中国科学院兰州化学物理研究所 从河套大黄中提取土大黄苷的方法
US10391096B2 (en) * 2011-10-13 2019-08-27 Quercegen Pharmaceuticals Llc Method for treating thrombotic disorders using quercetin-containing compositions
WO2013074948A1 (en) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
KR101996343B1 (ko) 2012-01-27 2019-07-05 고쿠리츠 다이가쿠 호진 교토 다이가쿠 전능성 줄기세포의 심근분화 유도방법
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US20140107154A1 (en) * 2012-10-12 2014-04-17 Teva Pharmaceutical Industries, Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
TWI485145B (zh) 2012-10-26 2015-05-21 財團法人工業技術研究院 Ｐ型有機半導體材料與光電元件
CA2894992A1 (en) * 2012-12-24 2014-07-03 Ramot At Tel-Aviv University Ltd. Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
CN103073605B (zh) * 2012-12-27 2015-07-08 成都普思生物科技有限公司 一种蒙花苷单体的分离纯化方法
WO2014136519A1 (ja) 2013-03-08 2014-09-12 国立大学法人京都大学 Ｅｇｆ受容体阻害剤を含む多能性幹細胞の心筋分化促進剤
US20140287021A1 (en) * 2013-03-21 2014-09-25 Panacea Pharmaceuticals Treatment of chemotherapy-induced peripheral neuropathy
KR101477407B1 (ko) * 2013-07-10 2014-12-29 국민대학교산학협력단 4,4'-비스(2-벤즈옥사졸일)스틸벤의 제조방법
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3038600B1 (en) * 2013-08-27 2020-06-03 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma
FR3015287B1 (fr) 2013-12-19 2016-12-23 Inst Nat Sante Rech Med Combinaison de bezafibrate et de resveratrol pour le traitement et la prevention des maladies impliquant un dysfonctionnement energetique des mitochondries.
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
WO2015154192A1 (en) * 2014-04-11 2015-10-15 George Robertson Use of a composition comprising a flavonol, a flavonoid, and a fatty acid in the treatment of oxidative injuries due to mitochondrial dysfunction
EA201692180A1 (ru) 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
EP3150705B1 (en) 2014-05-30 2019-05-15 Kyoto University Method for inducing myocardial differentiation of pluripotent stem cells using low-molecular compound
WO2016037171A1 (en) * 2014-09-05 2016-03-10 The Cleveland Clinic Foundation Flavonoid il-17a inhibitors
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
ITMI20141843A1 (it) 2014-10-27 2016-04-27 Giovannini Luca Associazioni sinergiche stimolanti l¿espressione di sirtuina 1
WO2016100444A1 (en) * 2014-12-16 2016-06-23 University Of Florida Research Foundation, Inc. Treatment of closed head injury and hemorrhagic stroke with hbed
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
JP6930969B2 (ja) * 2015-07-08 2021-09-01 ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療
EP3337469A4 (en) * 2015-08-20 2019-05-01 Paul A. Knepper COMPOSITION AND METHOD FOR INHIBITING THE THROMBOCYTE AGGREGATION
WO2017087685A1 (en) 2015-11-20 2017-05-26 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
JP7033789B2 (ja) 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用
WO2018187240A1 (en) * 2017-04-03 2018-10-11 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US20190108912A1 (en) * 2017-10-05 2019-04-11 Iquity, Inc. Methods for predicting or detecting disease
TWI644665B (zh) * 2017-12-08 2018-12-21 衛生福利部國家中醫藥研究所 Use of stilbene and benzofuran derivatives for the treatment of neurological diseases
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
CA3121235A1 (en) 2018-11-30 2020-06-04 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for reducing major thrombotic events in cancer patients
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
CN111096830B (zh) * 2019-12-28 2021-11-30 杭州电子科技大学 一种基于LightGBM的外骨骼步态预测方法
AU2021207815B2 (en) 2020-01-13 2026-03-26 The Feinstein Institutes For Medical Research Treating bleeding and bleeding disorders via high intensity focused ultrasound stimulation of the spleen
US20230110676A1 (en) * 2020-02-25 2023-04-13 Ergo-Health LLC Method of Treating Diseases
US20230116276A1 (en) * 2020-03-16 2023-04-13 William B. Coe Dietary supplement comprising aldehyde functional monoterpenoids
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
AU2022276190A1 (en) * 2021-05-19 2024-01-18 Quercis Pharma AG Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
WO2023288044A1 (en) 2021-07-16 2023-01-19 Beth Israel Deaconess Medical Center, Inc. Method for treating sickle cell disease using quercetin-containing compositions
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
FI4426434T3 (fi) 2021-11-02 2025-11-24 Flare Therapeutics Inc Pparg:n käänteisagonisteja ja niiden käyttöjä
WO2023086388A1 (en) * 2021-11-09 2023-05-19 YewSavin, Inc. Compositions and methods for treating bleeding and bleeding disorders
US20250229086A1 (en) 2022-01-20 2025-07-17 Setpoint Medical Corporation Treatment of inflammatory disorders
US11679078B1 (en) 2022-03-08 2023-06-20 EternaTear, Inc. Ophthalmic formulations and related methods
US20250312307A1 (en) * 2022-05-17 2025-10-09 Société des Produits Nestlé S.A. Compositions and methods using a combination of fisetin and quercetin for use in cartilage degeneration
JP2025516064A (ja) * 2022-05-17 2025-05-26 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 細胞エネルギーのためのフィセチンとケルセチンとの組み合わせを使用する組成物及び方法
JP7784085B2 (ja) * 2022-07-22 2025-12-11 長崎県公立大学法人 認知機能改善用の組成物、それを含む食品、薬剤、組成物キット、及び、その組成物の製造方法
CN115478105B (zh) * 2022-08-25 2023-06-30 郑州大学第一附属医院 Sirt4在肝缺血疾病治疗中的应用
WO2024233598A1 (en) * 2023-05-08 2024-11-14 YewSavin, Inc. Compositions and methods for treating bleeding and bleeding disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059561A2 (en) * 1998-05-18 1999-11-25 Hensley, Kenneth, L. Resveratrol inhibition of myeloperoxidase
WO2003103583A2 (en) * 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
WO2004045592A2 (en) * 2002-11-20 2004-06-03 Neuronova Ab Compounds and methods for increasing neurogenesis
WO2004078184A1 (en) * 2003-03-07 2004-09-16 Cambridge Biotechnology Ltd Use of adenosine receptor agonists in therapy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2543550B1 (fr) * 1983-04-01 1985-08-09 Cortial Nouveaux derives de la tetrahydroxy-3', 4',5,7 flavone, leur methode de preparation et leur emploi therapeutique
IL107642A0 (en) * 1992-11-20 1994-02-27 Amgen Inc Progenitor b cell stimulating factor
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
WO1999021565A1 (en) * 1997-10-24 1999-05-06 Cornell Research Foundation, Inc. Nutritional supplement for cerebral metabolic insufficiencies
IT1302365B1 (it) * 1998-10-09 2000-09-05 Sigma Tau Healthscience Spa Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
US6264995B1 (en) * 1999-10-19 2001-07-24 Thomas Newmark Herbal composition for reducing inflammation and methods of using same
US20020049176A1 (en) * 1999-11-10 2002-04-25 Anderson Christen M. Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
US7452664B2 (en) * 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
IT1317034B1 (it) * 2000-05-30 2003-05-26 Istituto Di Medicina Speriment Metodo di estrazione di prodotti ad attivita' farmaceutica da piantespermatofite, prodotti cosi' ottenuti e loro impiego in medicina, in
US6812248B2 (en) * 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
US20020110604A1 (en) * 2000-08-11 2002-08-15 Ashni Naturaceuticals, Inc. Composition exhibiting synergistic antioxidant activity
IT1320080B1 (it) * 2000-10-25 2003-11-18 Giuliani Spa Composizione per uso farmaceutico o dietetico.
US20020173549A1 (en) * 2000-11-08 2002-11-21 Wurtman Richard J. Compositions and methods for treatment of mild cognitive impairment
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
US6387416B1 (en) * 2001-04-05 2002-05-14 Thomas Newmark Anti-Inflammatory herbal composition and method of use
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
PT1390378E (pt) * 2001-04-30 2009-07-23 Trommsdorff Arzneimittel Ésteres de uridina farmaceuticamente activos
NZ516366A (en) * 2001-12-24 2004-07-30 Enzo Nutraceuticals Ltd Increased lifespan formulation using pine bark flavonoid extract
US20030199581A1 (en) * 2002-03-13 2003-10-23 Seligson Allen L. Boswellin compositions enhanced with 3-beta-acetyl-11-keto-beta-boswellic acid ("AKBA") industrial manufacture and uses
DE10230961A1 (de) * 2002-07-10 2004-02-12 Lorenz, Peter, Dr. Verwendung von Oxyresveratrol als Neuroprotektivum
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
CA2529510A1 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
US20050107338A1 (en) * 2003-11-17 2005-05-19 Seidman Michael D. Nutritional supplement enhancing mitochondrial function
EP1708689A2 (en) * 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
JP2008501343A (ja) * 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
WO2006007411A2 (en) * 2004-06-16 2006-01-19 President And Fellows Of Harvard College Methods and compositions for modulating bax-mediated apoptosis
US20060024385A1 (en) * 2004-07-27 2006-02-02 Pedersen Mark A Metabolic capacity enhancing compositions and methods for use in a mammal
WO2006079021A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1910385B1 (en) * 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059561A2 (en) * 1998-05-18 1999-11-25 Hensley, Kenneth, L. Resveratrol inhibition of myeloperoxidase
WO2003103583A2 (en) * 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
WO2004045592A2 (en) * 2002-11-20 2004-06-03 Neuronova Ab Compounds and methods for increasing neurogenesis
WO2004078184A1 (en) * 2003-03-07 2004-09-16 Cambridge Biotechnology Ltd Use of adenosine receptor agonists in therapy

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542296A (ja) * 2005-05-25 2008-11-27 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン活性化剤による眼障害の処置
JP2012500283A (ja) * 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク． （ｒ）−プラミペキソールを使用した組成物並びにその方法
JP2014510064A (ja) * 2011-02-25 2014-04-24 ザ ジョンズ ホプキンス ユニバーシティ Ｎｒｆ２活性剤としてのカルコン誘導体
KR101466700B1 (ko) * 2011-02-28 2014-11-28 동아대학교 산학협력단 Ｓｉｒ－ＦＯＸＯ 신호전달체계 활성인자를 포함하는 퇴행성 신경질환 치료용 조성물
JP2014516359A (ja) * 2011-04-15 2014-07-10 ネステク ソシエテ アノニム サーチュイン遺伝子発現の調節方法
JP2017206526A (ja) * 2011-06-29 2017-11-24 ザ ジェネラル ホスピタル コーポレイション 雌性生殖細胞における生体エネルギー状態を増強するための組成物及び方法
JP2019030326A (ja) * 2011-06-29 2019-02-28 ザ ジェネラル ホスピタル コーポレイション インビボで雌性生殖細胞の生体エネルギー状態を増強するための方法
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
JP2013241380A (ja) * 2012-05-22 2013-12-05 Apion Japan Kk サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤
JP2016507538A (ja) * 2013-02-07 2016-03-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 置換キノキサリン誘導体およびｍＧｌｕＲ４の正のアロステリックモジュレーターとしてのそれらの使用
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US10285981B2 (en) 2013-02-28 2019-05-14 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9956206B2 (en) 2013-02-28 2018-05-01 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
JP2016518448A (ja) * 2013-05-13 2016-06-23 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節剤としての置換架橋尿素類似体
US10383857B2 (en) 2013-07-12 2019-08-20 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
US10195183B2 (en) 2013-08-13 2019-02-05 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US10028940B2 (en) 2013-08-13 2018-07-24 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
US10456381B2 (en) 2013-08-13 2019-10-29 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
JP2016041680A (ja) * 2014-04-25 2016-03-31 森永製菓株式会社 サーチュイン発現増強剤
JP2016094406A (ja) * 2014-11-06 2016-05-26 森永製菓株式会社 アストロサイト分化誘導剤及びｇｆａｐ発現誘導剤
JP2018517728A (ja) * 2015-06-15 2018-07-05 ラッシュ・ユニバーシティ・メディカル・センター 脳由来のＰＰＡＲαリガンド
US11344524B2 (en) 2015-06-15 2022-05-31 Rush University Medical Center Brain derived PPARα ligands
KR101922903B1 (ko) 2016-03-11 2018-11-28 전북대학교산학협력단 항신경변성 천연물 소재의 스크리닝 방법
WO2020144753A1 (ja) * 2019-01-09 2020-07-16 公立大学法人大阪 神経変性疾患の予防又は治療薬
JPWO2020145331A1 (ja) * 2019-01-09 2021-11-25 株式会社メディラボRfp 神経変性疾患の予防又は治療薬
WO2020145331A1 (ja) * 2019-01-09 2020-07-16 公立大学法人大阪 神経変性疾患の予防又は治療薬
JP7279958B2 (ja) 2019-01-09 2023-05-23 株式会社メディラボRfp 神経変性疾患の予防又は治療薬
US12521387B2 (en) 2019-01-09 2026-01-13 Medilabo Rfp, Inc. Prophylactic or therapeutic drug for neurodegenerative diseases
WO2020153434A1 (ja) * 2019-01-25 2020-07-30 第一三共株式会社 ピラゾール化合物
JP2022523919A (ja) * 2019-02-05 2022-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 神経変性疾患を治療するための物質および方法
JP2024511616A (ja) * 2021-03-25 2024-03-14 ラモット アット テル アビブ ユニバーシティ， リミテッド 活性依存性神経栄養因子（ａｃｔｉｖｉｔｙ ｄｅｐｅｎｄｅｎｔ ｎｅｕｒｏｔｒｏｐｈｉｃ ｆａｃｔｏｒ、ａｄｎｆ）ポリペプチドを含む組成物及び物品
JP2022150176A (ja) * 2021-03-26 2022-10-07 国立大学法人九州大学 サーチュイン活性化剤、食品、および化粧品

Also Published As

Publication number Publication date
AU2006204699B2 (en) 2012-04-26
JP2013082723A (ja) 2013-05-09
WO2006076681A3 (en) 2007-06-28
US20060276393A1 (en) 2006-12-07
CA2595159A1 (en) 2006-07-20
WO2006076681A2 (en) 2006-07-20
AU2006204699A1 (en) 2006-07-20
EP1850840A2 (en) 2007-11-07

Similar Documents

Publication Publication Date Title
AU2006204699B2 (en) Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
AU2006269459B2 (en) Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
JP6559713B2 (ja) ニコチンアミドリボシド類似体ならびにその医薬組成物および使用
AU2006220554B2 (en) Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US20070248590A1 (en) Modulators of CDC2-like kinases (CLKS) and methods of use thereof
JP5203193B2 (ja) サーチュイン調節化合物としてのイミダゾ［２，１−ｂ］チアゾール誘導体
US20070149466A1 (en) Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
JP2008535790A (ja) サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体
US20150175645A1 (en) Nicotinamide riboside and analogues thereof
CA2595486A1 (en) Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
JP2014530870A (ja) サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
WO2022226191A1 (en) Methods of stabilizing the neuronal proteome against collapse and protecting vascular cells
Jain Neuroprotection in Alzheimer disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111124

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120223

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120223

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120817

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130410